Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation

作者全名："Daneshdoust, Danyal; Yin, Ming; Luo, Mingjue; Sundi, Debasish; Dang, Yongjun; Lee, Cheryl; Li, Jenny; Liu, Xuefeng"

作者地址："[Daneshdoust, Danyal; Yin, Ming; Luo, Mingjue; Sundi, Debasish; Lee, Cheryl; Li, Jenny; Liu, Xuefeng] Ohio State Univ, Comprehens Canc Ctr, USA ML, Columbus, OH 43210 USA; [Yin, Ming] Ohio State Univ, Wexner Med Ctr, Dept Med, Columbus, OH 43210 USA; [Sundi, Debasish; Lee, Cheryl] Ohio State Univ, Wexner Med Ctr, Dept Urol, Columbus, OH 43210 USA; [Dang, Yongjun] Chongqing Med Univ, Ctr Novel Target & Therapeut Intervent, Chongqing 400016, Peoples R China; [Liu, Xuefeng] Ohio State Univ, Wexner Med Ctr, Dept Pathol & Urol & Radiat Oncol, Columbus, OH 43210 USA"

通信作者："Liu, XF (通讯作者)，Ohio State Univ, Comprehens Canc Ctr, USA ML, Columbus, OH 43210 USA."

来源：CELLS

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:001028436500001

JCR分区：Q2

影响因子：5.1

年份：2023

卷号：12

期号：13

开始页：　

结束页：　

文献类型：Review

关键词：conditionally reprogrammed cells; bladder cancer; biomarkers; precision medicine; urine biomarkers

摘要："The use of advanced preclinical models has become increasingly important in drug development. This is particularly relevant in bladder cancer, where the global burden of disease is quite high based on prevalence and a relatively high rate of lethality. Predictive tools to select patients who will be responsive to invasive or morbid therapies (chemotherapy, radiotherapy, immunotherapy, and/or surgery) are largely absent. Patient-derived and clinically relevant models including patient-derived xenografts (PDX), organoids, and conditional reprogramming (CR) of cell cultures efficiently generate numerous models and are being used in both basic and translational cancer biology. These CR cells (CRCs) can be reprogrammed to maintain a highly proliferative state and reproduce the genomic and histological characteristics of the parental tissue. Therefore, CR technology may be a clinically relevant model to test and predict drug sensitivity, conduct gene profile analysis and xenograft research, and undertake personalized medicine. This review discusses studies that have utilized CR technology to conduct bladder cancer research."

基金机构："NIH [R01CA276474, R01CA222148, R33CA258016]"

基金资助正文："This research was funded by NIH grants: R01CA276474, R01CA222148, R33CA258016."